Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

Objective To compare the burden of multiple sclerosis disease indicators in the Asia-Pacific countries, China and globally through the Global Burden of Disease 2019 (GBD2019) Database, and to analyse the changes of multiple sclerosis disease burden in China from 1990 to 2019.Study design Observation...

Full description

Saved in:
Bibliographic Details
Main Authors: Min Li, Hua Zhong, Rong Jiang, Na Zhou, Shengnan Duan, Ni Yuan
Format: Article
Language:English
Published: BMJ Publishing Group 2022-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/12/e066335.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850148339990921216
author Min Li
Hua Zhong
Rong Jiang
Na Zhou
Shengnan Duan
Ni Yuan
author_facet Min Li
Hua Zhong
Rong Jiang
Na Zhou
Shengnan Duan
Ni Yuan
author_sort Min Li
collection DOAJ
description Objective To compare the burden of multiple sclerosis disease indicators in the Asia-Pacific countries, China and globally through the Global Burden of Disease 2019 (GBD2019) Database, and to analyse the changes of multiple sclerosis disease burden in China from 1990 to 2019.Study design Observational study based on the Global Burden of Disease.Setting The relevant incidence, prevalence, death and disability-adjusted life year (DALY) rates and corresponding age-standardised rates (ASRs) and sociodemographic index (SDI) in China, globally and in Asia-Pacific countries were extracted from the GBD2019 Database to further study the age-standardised incidence, prevalence and mortality, and the relationship between DALY rate and SDI.Results Various disease burden indicators of multiple sclerosis in China are at low level in the world, and the prevalence, incidence and DALY rates have slowly increased from 1990 to 2019. During this period, the age-standardised prevalence rate (ASPR) of multiple sclerosis in China showed an upward trend, while the age-standardised death rate (ASDR), age-standardised DALY rate (ASR-DALY) and age-standardised incidence rate all decreased to varying degrees, which were roughly consistent with the global amplitude changes, and all indicators are similar to most countries in the Asia-Pacific region. As the value of the SDI increases, the ASPR of multiple sclerosis was trending upward, and the ASDR was trending downward.Conclusion Compared with other countries in the Asia-Pacific region, China is in a low state of disease burden indicators. However, as a developing country and the most populous country in the world, the total number of patients is not small, and as a rare disease, the treatment cost is relatively expensive, and the treatment cost of the complications caused by the disease is not low. The construction of the medical security system should be strengthened to reduce its burden on individuals, families and society.
format Article
id doaj-art-9293bf1b33d3486c93b965c25f203e76
institution OA Journals
issn 2044-6055
language English
publishDate 2022-12-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open
spelling doaj-art-9293bf1b33d3486c93b965c25f203e762025-08-20T02:27:16ZengBMJ Publishing GroupBMJ Open2044-60552022-12-01121210.1136/bmjopen-2022-066335Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019Min Li0Hua Zhong1Rong Jiang2Na Zhou3Shengnan Duan4Ni Yuan52 Department of Bioinformatics and Systems Biology, Huazhong University of Science and Technology, Wuhan, ChinaShanghai Chest Hospital, Shanghai, ChinaCardio-Pulmonary Circulation, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, ChinaDepartment of Health Policy and Management, Peking University, Beijing, ChinaSchool of Public Health, Dalian Medical University, Dalian, Liaoning, ChinaSchool of Public Health, Dalian Medical University, Dalian, Liaoning, ChinaObjective To compare the burden of multiple sclerosis disease indicators in the Asia-Pacific countries, China and globally through the Global Burden of Disease 2019 (GBD2019) Database, and to analyse the changes of multiple sclerosis disease burden in China from 1990 to 2019.Study design Observational study based on the Global Burden of Disease.Setting The relevant incidence, prevalence, death and disability-adjusted life year (DALY) rates and corresponding age-standardised rates (ASRs) and sociodemographic index (SDI) in China, globally and in Asia-Pacific countries were extracted from the GBD2019 Database to further study the age-standardised incidence, prevalence and mortality, and the relationship between DALY rate and SDI.Results Various disease burden indicators of multiple sclerosis in China are at low level in the world, and the prevalence, incidence and DALY rates have slowly increased from 1990 to 2019. During this period, the age-standardised prevalence rate (ASPR) of multiple sclerosis in China showed an upward trend, while the age-standardised death rate (ASDR), age-standardised DALY rate (ASR-DALY) and age-standardised incidence rate all decreased to varying degrees, which were roughly consistent with the global amplitude changes, and all indicators are similar to most countries in the Asia-Pacific region. As the value of the SDI increases, the ASPR of multiple sclerosis was trending upward, and the ASDR was trending downward.Conclusion Compared with other countries in the Asia-Pacific region, China is in a low state of disease burden indicators. However, as a developing country and the most populous country in the world, the total number of patients is not small, and as a rare disease, the treatment cost is relatively expensive, and the treatment cost of the complications caused by the disease is not low. The construction of the medical security system should be strengthened to reduce its burden on individuals, families and society.https://bmjopen.bmj.com/content/12/12/e066335.full
spellingShingle Min Li
Hua Zhong
Rong Jiang
Na Zhou
Shengnan Duan
Ni Yuan
Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
BMJ Open
title Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
title_full Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
title_fullStr Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
title_full_unstemmed Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
title_short Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
title_sort burden and trends of multiple sclerosis in china from 1990 to 2019 a systematic analysis for the global burden of disease study 2019
url https://bmjopen.bmj.com/content/12/12/e066335.full
work_keys_str_mv AT minli burdenandtrendsofmultiplesclerosisinchinafrom1990to2019asystematicanalysisfortheglobalburdenofdiseasestudy2019
AT huazhong burdenandtrendsofmultiplesclerosisinchinafrom1990to2019asystematicanalysisfortheglobalburdenofdiseasestudy2019
AT rongjiang burdenandtrendsofmultiplesclerosisinchinafrom1990to2019asystematicanalysisfortheglobalburdenofdiseasestudy2019
AT nazhou burdenandtrendsofmultiplesclerosisinchinafrom1990to2019asystematicanalysisfortheglobalburdenofdiseasestudy2019
AT shengnanduan burdenandtrendsofmultiplesclerosisinchinafrom1990to2019asystematicanalysisfortheglobalburdenofdiseasestudy2019
AT niyuan burdenandtrendsofmultiplesclerosisinchinafrom1990to2019asystematicanalysisfortheglobalburdenofdiseasestudy2019